Angioplasty, Balloon, Coronary ; Coronary Restenosis ; therapy ; Humans ; Stents

Angioplasty, Balloon, Coronary ; Coronary Restenosis ; therapy ; Drug-Eluting Stents ; Humans

Angioplasty, Balloon, Coronary ; Coronary Disease ; pathology ; therapy ; Coronary Restenosis ; pathology ; Humans ; Thrombosis ; pathology

As an important medical instrument in percutaneous transluminal coronary angioplasty, endovascular stents must have excellent biocompatibility. In this paper, after a description of the performance and fabrication process of stents, we analyzed the technology to improve the biocompatibility of stents during the fabrication process which is the effective method for decreasing the rate of restenosis.
Angioplasty, Balloon, Coronary ; Animals ; Coronary Disease ; therapy ; Coronary Restenosis ; prevention & control ; Humans ; Stents

Coronary Restenosis ; prevention & control ; therapy ; Coronary Stenosis ; therapy ; Drug Delivery Systems ; Humans ; Medicine, Chinese Traditional ; methods ; Stents

In the era of drug-eluting stents (DESs), the angiographic rates of restenosis at later months have been dramatically reduced, but these rates have been less prominently reduced in diabetic patients. The rate of coronary restenosis is still higher in diabetic patients, when compared with non-diabetic patients, and even after DES implantation. Diabetes remains a significant predictor of coronary restenosis even in the era of DES, and especially in cases having a small baseline vessel size, a small post-PCI vessel size and a longer stent length. The use of the sirolimus-eluting stent in diabetic patients has been associated with a decreased rate of restenosis, and this suggests a reduced risk of target lesion revascularization. Diabetes still remains a major risk factor for coronary restenosis after DES implantation, and so aggressive risk factor management with the concomitant pharmacotherapy should be done to reduce the risk of coronary restenosis.
Coronary Restenosis* ; Drug Therapy ; Drug-Eluting Stents* ; Humans ; Risk Factors ; Stents

Coronary Restenosis ; therapy ; Drug-Eluting Stents ; adverse effects ; Humans ; Treatment Outcome

Coronary Restenosis ; etiology ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; therapy ; Stents ; Thrombosis ; etiology

OBJECTIVETo evaluate the safety and efficacy of drug-eluting stent (DES) implantation in selective patients with left main coronary artery disease.

METHODFrom October 2002 to November 2007, 44 consecutive patients underwent percutaneous coronary interventions (PCI) on left main coronary artery lesions, including 5 patients with concurrent left ventricular dysfunction (ejection fraction<40%), 2 with chronic respiratory dysfunction and 5 with chronic renal failure. The findings in coronary angiography, procedural success rate, severe complications and the follow-up results of the patients were analyzed.

RESULTSThe immediate procedural success rate was 100% in these patients without any severe complications. No non-fatal acute myocardial infarction or emergency coronary artery bypass grafting (CABG) was performed and death occurred in none of the cases during hospitalization. In the follow-up period for 14.2-/+9.3 (6-65) months after PCI, no subacute or late thromboses were found. One patient died from heart failure 4 months after PCI, and 6 patients (13.6%) experienced recurrent angina. Thirty-seven patients (84.1%) were free of any major cardiovascular events (MACE) after the procedure. A repeat coronary angiography was performed in 35 patients (79.5%) within 6 months after PCI, and 3 (8.6%) of them were confirmed to have restenosis, including 1 patient with distal bifurcation restenosis who were subsequently treated with CABG and two patients with side-branch ostium restenosis managed with cutting balloon dilation.

CONCLUSIONSImplantation of drug-eluting stents is safe and effective for management of left main coronary artery disease with good immediate and long-term outcomes.

Adult ; Aged ; Angioplasty, Balloon, Coronary ; Coronary Angiography ; Coronary Artery Disease ; therapy ; Coronary Restenosis ; therapy ; Drug-Eluting Stents ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Treatment Outcome

BACKGROUNDAlthough some certain infectious pathogens could be detected in the patients with coronary artery disease, the roles of these infectious factors in the development of coronary artery diseases remain largely unknown. Since the number of infectious pathogens has been argued to be relative to the coronary artery diseases, we therefore examined whether there is a link between the number of infections and the incidence of in-stent restenosis after stent implantation.

METHODSOne hundred and eighty-one patients were enrolled in this study. Infectious pathogens including serum anti-Chlymydia pneumoniae, cytomegalovirus, Helico pylori, human herpes simplex virus-1, human herpes simplex virus-2 antibodies and hepatitis B virus antigen were measured in all patients before coronary stent implantation. Coronary angiography was performed before, immediately after and 6 months after stent implantation.

RESULTSRestenosis rate 6 months post stent implantation was similar in patients with low pathogen burden (< 3 pathogens, 33.3%) to those with high pathogen burden (> or = 3 pathogens, 29.1%).

CONCLUSIONSPrevious infections with Chlymydia pneumoniae, cytomegalovirus, Helico pylori, human herpes simplex virus-1, human herpes simplex virus-2 and hepatitis B virus do not contribute to the incidence of restenosis after stent implantation.

Adult ; Aged ; Coronary Disease ; therapy ; Coronary Restenosis ; etiology ; Female ; Humans ; Infection ; complications ; Male ; Middle Aged ; Stents ; adverse effects